

Special Issue

Addiction: Molecular Research and Novel Therapeutic Approaches

Message from the Guest Editors

Addiction is a widespread, disabling condition, among the first causes of global burden of disease. Additional treatments are needed, and in order to proceed further, a clearer understanding of biological processes that underlie addiction is needed.

Molecular mechanisms play a vital role in this understanding. We need to integrate altered molecular pathways with disease expression, behavior, and neuronal circuitry, and to form a complete theory with significant clinical implications, both for diagnosis and treatment.

This Special Issue is dedicated to molecular research in the field of addiction. Both substance use disorders and novel behavioral addictions are to be considered the subject of the Issue. Manuscripts about biomarkers, genetics, pathophysiological mechanisms that underlie the disorder, and translational research are particularly welcome. On the side of treatments, manuscripts regarding pharmacological approaches are of particular interest for this Special Issue. Manuscripts dealing with non-pharmacological approaches with a strong biological rationale (e.g., neuromodulation techniques) are also welcome.

Guest Editors

Dr. Francesco Di Carlo

Dr. Giovanni Martinotti

Prof. Dr. Magi Farré

Deadline for manuscript submissions

closed (15 July 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/89417

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).